文献速递甲状腺疾病肥胖与代谢综合征

肥胖成人左甲状腺素替代治疗:代谢变量与年龄对甲状腺功能检测异常的影响

Levothyroxine Replacement in Obese Adults: The Role of Metabolic Variables and Aging on Thyroid Testing Abnormalities.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

该研究在4954例连续肥胖患者中分析691例接受左甲状腺素(LT4)治疗的原发性甲减患者及691例匹配的甲状腺功能正常对照。LT4使用者中TSH偏低者占7.5%、偏高者占17.2%、正常者占75.2%。过度替代随年龄增长而减少,年龄、体成分和性别是肥胖者LT4需求的主要决定因素。

要点

  • 肥胖LT4使用者中甲状腺功能异常率(偏低7.5%、偏高17.2%)相对温和。
  • 过度替代风险随年轻化、高LT4剂量和低BMI增加,男性低估风险更高。
  • 去脂体重、甲减病因和性别可预测LT4剂量。

核心结论

  • 与非肥胖人群相比,肥胖与较轻的LT4治疗不足率相关。
  • LT4 adequacy随年龄增长而增加。
  • 年龄、体成分和性别是肥胖者LT4需求的主要决定因素。

研究设计与样本

  • tertiary care center的回顾性分析,纳入2011至2014年间4954例连续肥胖患者。
  • 691例接受LT4治疗的原发性甲减患者与691例按BMI、年龄和性别匹配的甲状腺功能正常对照。
  • 所有对象接受甲状腺功能、糖脂谱、体成分和间接测热法分析。

主要发现

  • LT4使用者占新入人群的13.9%。
  • LT4使用者中TSH偏低者占7.5%、偏高者占17.2%、正常者占75.2%。
  • 过度替代随年龄增长而减少,≥65岁LT4使用者中TSH正常者比例高于<65岁者(P < 0.05)。
  • 与甲状腺功能正常的肥胖组相比,LT4使用者体脂更高、胰岛素抵抗相似但脂质谱更健康。
  • 多变量分析中,LT4剂量由去脂体重、甲减病因和性别预测(P < 0.0001至< 0.05)。

关键数值与推荐

  • LT4过度替代风险随年轻年龄(OR 0.96;95% CI 0.94至0.99)、较高LT4剂量(OR 2.98;95% CI 1.44至6.14)和较低BMI(OR 0.93;95% CI 0.88至0.99)增加。
  • 男性性别增加LT4替代不足的可能性(OR 2.37;95% CI 1.10至5.11)。
  • TSH分类标准:偏低<0.27 mU/L,正常0.27至4.2 mU/L,偏高>4.2 mU/L。

临床怎么用

  • 肥胖甲减患者LT4替代时应考虑年龄、体成分和性别对剂量的影响。
  • 年轻、高剂量和低BMI的肥胖LT4使用者需警惕过度替代。
  • 男性肥胖LT4使用者需关注替代不足风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: General rates of over- and underreplacement in levothyroxine (LT4) users with primary hypothyroidism are variably high. No information on LT4 adequacy exists in obesity. OBJECTIVE: We explored rates and factors relating to LT4 adequacy in obese patients with primary hypothyroidism. SETTING: Tertiary care center. DESIGN: Among 4954 consecutive obese patients admitted between 2011 and 2014, 691 hypothyroid patients receiving LT4 therapy and 691 body mass index (BMI)-, age-, and sex-matched euthyroid controls underwent analysis of thyroid function, glucolipid profile, body composition, and indirect calorimetry. LT4 users were classified into low TSH (<0.27 mU/L), euthyroid (0.27 to 4.2 mU/L), and high TSH (>4.2 mU/L). RESULTS: LT4 users constituted 13.9% of the incident population. TSH was low in 7.5%, high in 17.2%, and normal in 75.2% of LT4 users. Overtreatment decreased with aging and more LT4 users ≥65 years of age had normal TSH than those <65 years of age (P < 0.05). Compared with the euthyroid obese group, LT4 users showed higher adiposity, similar insulin resistance, but a healthier lipid profile. In multivariable analyses, LT4 dose was predicted by fat-free mass, hypothyroidism cause, and sex (P < 0.0001 to < 0.05). Risk of LT4 overreplacement increased with younger age (OR 0.96; 95% CI 0.94 to 0.99), higher LT4 dose (OR 2.98; 95% CI 1.44 to 6.14), and lower BMI (OR 0.93; 95% CI 0.88 to 0.99). Male sex increased the likelihood of LT4 underreplacement (OR 2.37; 95% CI 1.10 to 5.11). CONCLUSIONS: Obesity is associated with milder rates of inadequate LT4 treatment compared with nonobese populations. LT4 adequacy increases with aging. Age, body composition, and sex are main determinants of LT4 requirements in obesity.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Mele C, Tagliaferri MA, Pagano L, et al. Levothyroxine Replacement in Obese Adults: The Role of Metabolic Variables and Aging on Thyroid Testing Abnormalities. J Clin Endocrinol Metab. 2019. PMID: 31265068. doi:10.1210/jc.2019-00773

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。